InvestSMART

Recce Pharmaceuticals Ltd (ASX: RCE) - Announcements

Current share price for RCE : $0.365 0.01 (2.67%)+

ASX company news and announcements for Recce Pharmaceuticals Ltd (RCE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Recce Pharmaceuticals Ltd (RCE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Recce Pharmaceuticals Ltd (RCE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Recce Pharmaceuticals Ltd (RCE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$112 Funding Update 13 Sep 2018 12:52PM $0.180 $0.365 risen by 102.78%
$112 Investor Presentation 12 Sep 2018 10:01AM $0.180 $0.365 risen by 102.78%
$112 Investor Presentation 4 Sep 2018 4:15PM $0.180 $0.365 risen by 102.78%
$112 Appendix 4E - Preliminary Final Report 31 Aug 2018 4:07PM $0.185 $0.365 risen by 97.30%
$112 Key Australian Patent for Recce's Broad-Spectrum Antibiotics 31 Jul 2018 12:37PM $0.180 $0.365 risen by 102.78%
$112 Appendix 4C and commentary 30 Jul 2018 4:06PM $0.180 $0.365 risen by 102.78%
$112 Update on Progress of Broad Spectrum Antibiotic RECCE 327 17 Jul 2018 10:07AM $0.180 $0.365 risen by 102.78%
$112 Change of Share Registry 16 Jul 2018 10:01AM $0.180 $0.365 risen by 102.78%
$112 Recce Presented at FNN/Shaw and Partners Investor Conference 21 Jun 2018 9:50AM $0.180 $0.365 risen by 102.78%
$112 Update on meeting with US FDA 5 Jun 2018 10:26AM $0.175 $0.365 risen by 108.57%
$112 Investor Presentation 5 Jun 2018 9:08AM $0.175 $0.365 risen by 108.57%
$112 Recce Pharmaceuticals to Present at Investor Conference 30 May 2018 4:29PM $0.190 $0.365 risen by 92.11%
$112 Update on meeting with US FDA 16 May 2018 1:24PM $0.165 $0.365 risen by 121.21%
$112 Cleansing Statement 1 May 2018 5:27PM $0.155 $0.365 risen by 135.48%
$112 Appendix 3B 1 May 2018 5:22PM $0.155 $0.365 risen by 135.48%
$112 Appendix 4C and commentary 30 Apr 2018 5:22PM $0.155 $0.365 risen by 135.48%
$112 Initial Director's Interest Notice 27 Apr 2018 9:33AM $0.185 $0.365 risen by 97.30%
$112 Pharmaceutical Expert Joins Board of Directors 24 Apr 2018 9:09AM $0.180 $0.365 risen by 102.78%
$112 Additional AU$861,590 R&D Tax Incentive Rebate Received 23 Apr 2018 8:57AM $0.145 $0.365 risen by 151.72%
$112 RECCE Antibiotic International Media Attention 19 Apr 2018 3:09PM $0.140 $0.365 risen by 160.71%
$112 April Funding Update 28 Mar 2018 11:07AM $0.150 $0.365 risen by 143.33%
$112 Meeting with US FDA on Phase I Clinical Trial for RECCE 327 8 Mar 2018 10:17AM $0.165 $0.365 risen by 121.21%
$112 Recce Half Yearly Report and Appendix 4D 28 Feb 2018 5:44PM $0.170 $0.365 risen by 114.71%
$112 Cleansing Statement 16 Feb 2018 4:53PM $0.170 $0.365 risen by 114.71%
$112 Appendix 3B 16 Feb 2018 4:50PM $0.170 $0.365 risen by 114.71%

551 - 575 of 725 results

Page 23 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.